Our Pipeline

    Proprietary NCEs at different stages of development


    SUVN-502 is a pure 5-HT6receptor antagonist with >1200-fold selectivity over 5-HT2A receptor with a superior profile that differentiates from competitor 5-HT6 antagonists. SUVN-502 has an excellent human pharmacokinetics for once a day treatment.


    A potent, selective, brain penetrant and orally active Histamine H3 inverse agonist for the treatment of cognitive dysfunction associated with AD / Schizophrenia. SUVN-G3031 completed all the Pre-clinical, Safety, early Tox and GLP Tox studies.US IND has been approved in Sept-2014.


    SUVN-D4010 – A US-IND approved drug candidate is undergoing phase 1 studies in USA. SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s and Schizophrenia.


    SUVN-911 – A selective alpha-4-beta-2 ligand for the treatment of major depressive disorders (MDD).

    Clinical Development

    Clinical Development

    About Us

    Suven Neurosciences, Inc. a Delaware company, a wholly owned subsidiary of Suven Life Sciences Limited, India, is a clinical-stage biopharmaceutical company focused on acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven Life Sciences' discovery research programs are focused on discovering and developing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets, having world wide patents. Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D-4010 for Alzheimer’s disease and Schizophrenia. In addition, the Company has Ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

    Health for patients and value for partners